Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chondrocell-EX
- Development stage
- Unknown
- Lead developer
- Cytopeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Chondrocell-EX is an allogeneic cell therapy product composed of human umbilical cord-derived mesenchymal stem cells (UC-MSCs), developed by Cytopeutics Sdn. Bhd. for the treatment of knee articular cartilage defects and osteoarthritis. The therapy leverages the regenerative potential of mesenchymal stem cells, which possess the ability to differentiate into chondrocytes and promote the formation of hyaline-like cartilage (Type II collagen) rather than fibrocartilage. Additionally, the cells exhibit immunomodulatory properties that help manage the inflammatory environment within the synovial joint. Chondrocell-EX is specifically targeted at moderately-severe knee articular cartilage defects (ICRS grade 3) and is currently being evaluated in Phase II clinical trials to assess its efficacy compared to standard surgical procedures such as marrow cellution.
- Brand names
- Chondrocell-EX
- Other names
- Allogeneic umbilical cord-derived mesenchymal stem cellshUC-MSCsUC-MSCs
Beyond the preview
Go deeper on Chondrocell-EX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chondrocell-EX.